<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
The investment arm of Novo Nordisk AS (NVO) just added to its long list of life science companies, thrusting the Danish pharma giant into the growing market for diagnostics. Novo paid $563 million to become the majority shareholder of U.K.-based BBI Group, a world leader in producing diagnostic reagents and supplies for other test makers.
...read full article on GuruFocus
